Systemic testosterone treatment is linked to a delayed decrease in the use of inhaled corticosteroids among men with obstructive airway disease, according to a nationwide cohort study published in Respiratory Medicine. While patients showed a reduction in corticosteroid reliance 18 to 24 months after starting therapy, those older than 45 experienced a simultaneous increase in the use of short-acting beta-agonists (SABA), suggesting a complex shift in respiratory management.
How Does Testosterone Affect Respiratory Medication Patterns?
The study, which tracked 858 men using national Danish health and prescription registries between 1995 and 2022, found that testosterone therapy does not produce immediate changes in airway medication use. Hansen, inhaled corticosteroid exposure remained stable for the first 18 months of treatment. A statistically significant reduction—averaging 54 μg in budesonide-equivalent dose—did not occur until the 18-to-24-month window.
This delayed response suggests that if testosterone influences airway inflammation, it may do so through a gradual immunomodulatory process. The reduction in corticosteroid reliance was most pronounced in participants diagnosed with chronic obstructive pulmonary disease (COPD), rather than those with asthma or mixed asthma-COPD phenotypes.
The researchers utilized a within-subject design, meaning they compared each participant’s medication usage patterns against their own history both before and after starting testosterone therapy to account for individual baseline differences.
Why Is SABA Use Increasing in Older Patients?
Despite the long-term reduction in inhaled corticosteroids, the study identified a concerning trend regarding reliever medications. Among men older than 45, the use of short-acting beta-agonists (SABA) increased by a mean of 111 doses per half-year following the initiation of androgen therapy. While the overall cohort did not reach statistical significance for this increase, the trend in older adults highlights a potential clinical conflict.
According to the findings, while systemic testosterone might influence underlying inflammatory pathways, it does not necessarily translate to improved symptom control for all patients. The authors note that the numerical trend toward higher annualized exacerbation rates, despite the reduction in controller medication, warrants caution. Clinicians should monitor patients closely for increased reliance on rescue inhalers when initiating testosterone therapy, particularly in those with pre-existing obstructive lung conditions.
Pro Tips for Managing Respiratory Health
- Monitor for Delayed Effects: Respiratory changes related to hormonal therapy may take over a year to manifest, making long-term consistent monitoring essential.
Frequently Asked Questions
Does testosterone treatment cure COPD or asthma?
No. The study indicates that testosterone therapy may alter the dosage requirements for inhaled corticosteroids in some patients, but it is not a treatment for COPD or asthma.
Why is there a delay in medication changes?
The authors suggest that any potential immunomodulatory effects of testosterone on the airways likely occur gradually over time, rather than providing an immediate therapeutic impact.
Should patients worry about increased exacerbations?
While the study observed numerical trends toward higher exacerbation rates, these were not statistically significant. However, the authors advise careful monitoring due to the observed rise in SABA use among older adults.
For more insights on managing chronic respiratory conditions and the latest clinical research, subscribe to our newsletter or explore our respiratory health archive. Have you noticed changes in your symptoms after starting a new medication? Share your experience in the comments below.
